Osimertinib Cements Lead in EGFR Lung Cancer as AstraZeneca Updates Key Phase 3 Trial
AstraZeneca ($~AZN) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: AstraZeneca’s phase 3 trial NCT02296125, “AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,” compares first line treatment options in a targeted lung cancer group. The study looks at whether AZD9291, now known as osimertinib, offers better disease control and survival than older drugs, a key question for AZN’s oncology growth story.
Intervention/Treatment: The trial tests oral osimertinib against standard epidermal growth factor receptor (EGFR) pills erlotinib and gefitinib plus matching placebos. All drugs are once daily tablets aimed at slowing or stopping tumor growth in EGFR mutation positive non small cell lung cancer, a segment where targeted therapy has reshaped treatment and branded pricing power remains high.
Study Design: This is a randomized study, meaning patients are assigned by chance to receive either osimertinib or a standard EGFR drug. It uses a parallel, triple blind design, so patients, doctors, and trial assessors do not know who is on which therapy, and the main goal is to measure treatment benefit, especially how long patients live without their cancer getting worse.
Study Design: The primary outcome is progression free survival, or time until the cancer grows or the patient dies, with key secondary measures including response rate and overall survival. Results posted show osimertinib cut the risk of disease progression roughly in half versus standard care and improved disease control and response depth, while overall survival also favored osimertinib with a modest but statistically significant benefit.
Study Timeline: The study was first submitted on 2014-10-22, marking the early investment phase when AZN was still validating osimertinib as a first line option. Primary and key secondary results were first posted on 2018-06-13, giving the market clear evidence that the drug could outperform legacy EGFR therapies.
Study Timeline: The trial is now listed as completed, with the most recent update submitted on 2026-04-20, confirming ongoing data curation and follow up. This fresh update suggests that long term survival, safety, and real world like measures continue to hold up, which is important for pricing, label strength, and payer support.
Market Implications: Osimertinib is already a major revenue pillar for AstraZeneca, and these updated phase 3 data reinforce its status as the preferred first line EGFR lung cancer therapy. Stronger or sustained progression free and overall survival signals support durable demand, higher treatment duration, and help protect premium pricing, all of which are supportive for AZN’s medium term earnings profile.
Market Implications: For investors, the latest update reduces clinical risk and makes it harder for older EGFR drugs or cheaper generics from rivals like Roche (Tarceva) or generic gefitinib makers to regain share. The study also strengthens AZN’s position against newer targeted and combination regimens by underlining the benchmark that future entrants must beat, and could support continued positive sentiment around AZN’s oncology franchise and valuation multiple.
Market Implications: While incremental share price moves may be limited given osimertinib’s success is well known, confirmation of benefit and long term safety narrows downside risk from unexpected data surprises. The data also provide a strong platform for lifecycle strategies, including combinations and new indications, which can extend the drug’s cash flow window beyond earlier expectations.
Closing Sentence: The trial is completed and has recently been updated, with full and detailed information available to investors and clinicians on the ClinicalTrials.gov portal.
To learn more about ~AZN’s potential, visit the AstraZeneca drug pipeline page.
Disclaimer & DisclosureReport an Issue
